|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
v
3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET
1 Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
2 Department of Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
3 Department of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
* To whom correspondence should be addressed. E-mail: beer{at}roe.med.tum.de.
| Abstract |
|---|
The integrin
v
3 is a key player in angiogenesis and metastasis. Our aim was to study the uptake patterns of the
v
3-selective PET tracer 18F-galacto-RGD in invasive ductal breast cancer. Methods: Sixteen patients with primary (n = 12) or metastasized breast cancer (n = 4) were examined with 18F-galacto-RGD PET. Standardized uptake values (SUVs) were derived by region-of-interest analysis, and immunohistochemistry of
v
3 expression was performed (n = 5). Results: 18F-Galacto-RGD PET identified all invasive carcinomas, with SUVs from 1.4 to 8.7 (mean ± SD, 3.6 ± 1.8; tumor-to-blood and tumor-to-muscle ratios, 2.7 ± 1.6 and 6.2 ± 2.2, respectively). Lymph-node metastases were detected in 3 of 8 patients (mean SUV, 3.3 ± 0.8). SUVs in distant metastases were heterogeneous (2.9 ± 1.4). Immunohistochemistry confirmed
v
3 expression predominantly on microvessels (5/5) and, to a lesser extent, on tumor cells (3/5). Conclusion: Our results suggest generally elevated and highly variable
v
3 expression in human breast cancer lesions. Consequently, further imaging studies with 18F-galacto-RGD PET in breast cancer patients for assessment of angiogenesis or planning of
v
3-targeted therapies are promising.
Key Words:
breast cancer, integrins,
v
3, angiogenesis, PET, RGD
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |